Proprietary Name,NDC Package Code,Strength,Dosage Form,Route,Appl. No.,Labeler Name,Product NDC,Nonproprietary Name,Substance Name,Product Type Name,Start Marketing Date,End Marketing Date,Market Category,Package Description,Pharm Class,DEA,Sample Package,Listing Record Certified Through:
BELBUCA (U),55700-867-60, , , , ,"Quality Care Products, LLC", , , , , ,N/A, , ,N/A,N/A,N/A, 
BUPRENORPHINE (U),68071-2592-3, , , , ,"NuCare Pharmaceuticals,Inc.", , , , , ,N/A, , ,N/A,N/A,N/A, 
BUPRENORPHINE (U),50090-5805-0, , , , ,A-S Medication Solutions, , , , , ,N/A, , ,N/A,N/A,N/A, 
Buprenorphine and Naloxone (U),70518-3129-0, , , , ,REMEDYREPACK INC., , , , , ,N/A, , ,N/A,N/A,N/A, 
buprenorphine hydrochloride (U),50090-1571-0, , , , ,A-S Medication Solutions, , , , , ,N/A, , ,N/A,N/A,N/A, 
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE (U),16729-549-10, , , , ,"Accord Healthcare, Inc", , , , , ,N/A, , ,N/A,N/A,N/A, 
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE (U),16729-550-10, , , , ,"Accord Healthcare, Inc", , , , , ,N/A, , ,N/A,N/A,N/A, 
Buprenex,12496-0757-5,.3 mg/mL,INJECTION,INTRAMUSCULAR; INTRAVENOUS,NDA018401,Indivior Inc.,12496-0757,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,06/30/1985,N/A,NDA,5 AMPULE in 1 CARTON (12496-0757-5)  / 1 mL in 1 AMPULE (12496-0757-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride,0409-2012-32,.3 mg/mL,"INJECTION, SOLUTION",INTRAMUSCULAR; INTRAVENOUS,ANDA074137,"Hospira, Inc.",0409-2012,Buprenorphine Hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,06/14/2005,N/A,ANDA,10 CARTRIDGE in 1 CARTON (0409-2012-32)  / 1 mL in 1 CARTRIDGE (0409-2012-03),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride,0143-9246-05,.324 mg/mL,INJECTION,INTRAMUSCULAR; INTRAVENOUS,ANDA076931,Hikma Pharmaceuticals USA Inc.,0143-9246,Buprenorphine Hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/12/2019,N/A,ANDA,5 VIAL in 1 CARTON (0143-9246-05)  / 1 mL in 1 VIAL (0143-9246-01),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride,42023-179-05,.324 mg/mL,INJECTION,INTRAMUSCULAR; INTRAVENOUS,ANDA206586,"Par Pharmaceutical, Inc.",42023-179,Buprenorphine Hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/30/2015,N/A,ANDA,5 VIAL in 1 CARTON (42023-179-05)  / 1 mL in 1 VIAL,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Zubsolv,54123-907-30,".7 mg/1,                         .18  mg/1","TABLET, ORALLY DISINTEGRATING",SUBLINGUAL,NDA204242,"Orexo US, Inc.",54123-907,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/04/2013,N/A,NDA,"3 BLISTER PACK in 1 CARTON (54123-907-30)  / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Zubsolv,54123-914-30,"1.4 mg/1,                         .36  mg/1","TABLET, ORALLY DISINTEGRATING",SUBLINGUAL,NDA204242,"Orexo US, Inc.",54123-914,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/04/2013,N/A,NDA,"3 BLISTER PACK in 1 CARTON (54123-914-30)  / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0093-3657-40,10 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA204937,"Teva Pharmaceuticals USA, Inc.",0093-3657,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,11/26/2018,N/A,ANDA,4 POUCH in 1 CARTON (0093-3657-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,42858-493-40,10 ug/h,PATCH,TRANSDERMAL,NDA021306,Rhodes Pharmaceuticals L.P.,42858-493,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,07/05/2017,N/A,NDA AUTHORIZED GENERIC,4 POUCH in 1 CARTON (42858-493-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,69238-1203-2,10 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA211586,Amneal Pharmaceuticals NY LLC,69238-1203,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,04/20/2020,N/A,ANDA,4 POUCH in 1 CARTON (69238-1203-2)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine transdermal system,47781-407-04,10 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA207490,Alvogen Inc.,47781-407,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,08/29/2022,N/A,ANDA,4 POUCH in 1 CARTON (47781-407-04)  / 1 PATCH in 1 POUCH (47781-407-11)  / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Butrans,59011-751-04,10 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,NDA021306,Purdue Pharma LP,59011-751,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/14/2011,N/A,NDA,4 POUCH in 1 CARTON (59011-751-04)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
SUBLOCADE,12496-0100-1,100 mg/1,SOLUTION,SUBCUTANEOUS,NDA209819,Indivior Inc.,12496-0100,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/26/2018,N/A,NDA,1 POUCH in 1 CARTON (12496-0100-1)  / 1 SYRINGE in 1 POUCH (12496-0100-2)  / 1 SOLUTION in 1 SYRINGE (12496-0100-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Zubsolv,54123-114-30,"11.4 mg/1,                         2.9  mg/1","TABLET, ORALLY DISINTEGRATING",SUBLINGUAL,NDA204242,"Orexo US, Inc.",54123-114,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,12/11/2014,N/A,NDA,"3 BLISTER PACK in 1 CARTON (54123-114-30)  / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,0378-8768-93,"12 mg/1,                         3  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA207607,Mylan Pharmaceuticals Inc.,0378-8768,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/20/2019,N/A,ANDA,30 POUCH in 1 CARTON (0378-8768-93)  / 1 FILM in 1 POUCH (0378-8768-16),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,47781-358-03,"12 mg/1,                         3  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA205954,Alvogen Inc.,47781-358,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/11/2019,N/A,ANDA,30 POUCH in 1 CARTON (47781-358-03)  / 1 FILM in 1 POUCH (47781-358-11),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,60505-7054-5,"12 mg/1,                         3  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA212756,Apotex Corp.,60505-7054,buprenorphine and naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,12/12/2022,N/A,ANDA,30 POUCH in 1 CARTON (60505-7054-5)  / 1 FILM in 1 POUCH (60505-7054-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,43598-581-30,"12 mg/1,                         3  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,ANDA205806,Dr.Reddys Laboratories Inc,43598-581,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/14/2018,N/A,ANDA,"30 POUCH in 1 CARTON (43598-581-30)  / 1 FILM, SOLUBLE in 1 POUCH (43598-581-01)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Suboxone,12496-1212-3,"12 mg/1,                         3  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,NDA022410,INDIVIOR INC.,12496-1212,"buprenorphine hydrochloride, naloxone hydrochloride",BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,08/24/2012,N/A,NDA,"30 POUCH in 1 CARTON (12496-1212-3)  / 1 FILM, SOLUBLE in 1 POUCH (12496-1212-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,42858-586-40,15 ug/h,PATCH,TRANSDERMAL,NDA021306,Rhodes Pharmaceuticals L.P.,42858-586,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,07/05/2017,N/A,NDA AUTHORIZED GENERIC,4 POUCH in 1 CARTON (42858-586-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,69238-1204-2,15 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA211586,Amneal Pharmaceuticals NY LLC,69238-1204,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,04/20/2020,N/A,ANDA,4 POUCH in 1 CARTON (69238-1204-2)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0093-3658-40,15 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA204937,"Teva Pharmaceuticals USA, Inc.",0093-3658,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,11/26/2018,N/A,ANDA,4 POUCH in 1 CARTON (0093-3658-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine transdermal system,47781-419-04,15 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA207490,Alvogen Inc.,47781-419,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,08/29/2022,N/A,ANDA,4 POUCH in 1 CARTON (47781-419-04)  / 1 PATCH in 1 POUCH (47781-419-11)  / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Butrans,59011-758-04,15 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,NDA021306,Purdue Pharma LP,59011-758,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/14/2011,N/A,NDA,4 POUCH in 1 CARTON (59011-758-04)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-022-60,150 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-022,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/01/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-022-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-022-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-8,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (71335-0353-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-6,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,1 TABLET in 1 BOTTLE (71335-0353-6),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-2,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/13/2018,N/A,ANDA,90 TABLET in 1 BOTTLE (71335-0950-2),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-4,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2022,N/A,ANDA,7 TABLET in 1 BOTTLE (71335-0950-4),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,62756-459-83,2 mg/1,TABLET,SUBLINGUAL,ANDA201760,"Sun Pharmaceutical Industries, Inc.",62756-459,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/17/2016,N/A,ANDA,30 TABLET in 1 BOTTLE (62756-459-83),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-3,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-0353-3),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-5,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,28 TABLET in 1 BOTTLE (71335-0353-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-4,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,7 TABLET in 1 BOTTLE (71335-0353-4),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-2,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,90 TABLET in 1 BOTTLE (71335-0353-2),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-8,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (71335-0950-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0228-3156-03,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,"Actavis Pharma, Inc.",0228-3156,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/10/2015,N/A,ANDA,30 TABLET in 1 BOTTLE (0228-3156-03),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-1,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,60 TABLET in 1 BOTTLE (71335-0353-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,42858-501-03,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Rhodes Pharmaceuticals L.P.,42858-501,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/25/2017,N/A,ANDA,30 TABLET in 1 BOTTLE (42858-501-03),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,62756-459-64,2 mg/1,TABLET,SUBLINGUAL,ANDA201760,"Sun Pharmaceutical Industries, Inc.",62756-459,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/17/2016,N/A,ANDA,3 BLISTER PACK in 1 CARTON (62756-459-64)  / 10 TABLET in 1 BLISTER PACK,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-5,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2022,N/A,ANDA,28 TABLET in 1 BOTTLE (71335-0950-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-7,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2022,N/A,ANDA,12 TABLET in 1 BOTTLE (71335-0950-7),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,58118-0501-8,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,"Clinical Solutions Wholesale, LLC",58118-0501,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/25/2017,N/A,ANDA,30 TABLET in 1 BLISTER PACK (58118-0501-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-6,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2022,N/A,ANDA,1 TABLET in 1 BOTTLE (71335-0950-6),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,60687-481-21,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,American Health Packaging,60687-481,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/06/2020,N/A,ANDA,"30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-481-21)  / 1 TABLET in 1 BLISTER PACK (60687-481-11)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,71335-0353-7,2 mg/1,TABLET,SUBLINGUAL,ANDA090819,Bryant Ranch Prepack,71335-0353,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/02/2022,N/A,ANDA,12 TABLET in 1 BOTTLE (71335-0353-7),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,63629-9475-1,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,63629-9475,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,11/28/2022,N/A,ANDA,30 TABLET in 1 BOTTLE (63629-9475-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-1,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/13/2018,N/A,ANDA,60 TABLET in 1 BOTTLE (71335-0950-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-0950-3,2 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-0950,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2022,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-0950-3),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,0054-0176-13,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,Hikma Pharmaceuticals USA Inc.,0054-0176,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/08/2009,N/A,ANDA,30 TABLET in 1 BOTTLE (0054-0176-13),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,70518-2226-0,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,REMEDYREPACK INC.,70518-2226,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/19/2019,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-2226-0),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,70518-2226-1,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,REMEDYREPACK INC.,70518-2226,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,05/12/2020,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (70518-2226-1)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,70518-2226-2,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,REMEDYREPACK INC.,70518-2226,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/04/2021,N/A,ANDA,"60 TABLET in 1 BOTTLE, PLASTIC (70518-2226-2)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,70518-2226-3,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,REMEDYREPACK INC.,70518-2226,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/04/2021,N/A,ANDA,"90 TABLET in 1 BOTTLE, PLASTIC (70518-2226-3)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,0904-7154-04,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,Major Pharmaceuticals,0904-7154,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/08/2009,N/A,ANDA,30 BLISTER PACK in 1 CARTON (0904-7154-04)  / 1 TABLET in 1 BLISTER PACK,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,58118-0176-8,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,"Clinical Solutions Wholesale, LLC",58118-0176,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/15/2018,N/A,ANDA,30 TABLET in 1 BLISTER PACK (58118-0176-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,55700-302-30,2 mg/1,TABLET,SUBLINGUAL,ANDA078633,Lake Erie Medical DBA Quality Care Products LLC,55700-302,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/23/2015,N/A,ANDA,30 TABLET in 1 BOTTLE (55700-302-30),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-1,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/31/2016,N/A,ANDA,60 TABLET in 1 BOTTLE (63629-7125-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-2,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/31/2016,N/A,ANDA,90 TABLET in 1 BOTTLE (63629-7125-2),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-3,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/21/2017,N/A,ANDA,30 TABLET in 1 BOTTLE (63629-7125-3),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-4,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,7 TABLET in 1 BOTTLE (63629-7125-4),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-5,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,28 TABLET in 1 BOTTLE (63629-7125-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-6,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,1 TABLET in 1 BOTTLE (63629-7125-6),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-7,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,12 TABLET in 1 BOTTLE (63629-7125-7),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,63629-7125-8,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Bryant Ranch Prepack,63629-7125,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (63629-7125-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,50383-924-93,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,Akorn Operating Company LLC (dba Akorn),50383-924,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/24/2010,N/A,ANDA,30 TABLET in 1 BOTTLE (50383-924-93),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,70518-2216-0,2 mg/1,TABLET,SUBLINGUAL,ANDA090622,REMEDYREPACK INC.,70518-2216,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/15/2019,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-2216-0),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2024
Buprenorphine and Naloxone,0228-3154-03,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA091422,"Actavis Pharma, Inc.",0228-3154,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,03/04/2013,N/A,ANDA,30 TABLET in 1 BOTTLE (0228-3154-03),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,60687-626-65,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205601,American Health Packaging,60687-626,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,11/01/2021,N/A,ANDA,50 BLISTER PACK in 1 CARTON (60687-626-65)  / 1 TABLET in 1 BLISTER PACK (60687-626-11),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,0378-8765-93,"2 mg/1,                         .5  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA211785,Mylan Pharmaceuticals Inc.,0378-8765,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,04/17/2020,N/A,ANDA,30 POUCH in 1 CARTON (0378-8765-93)  / 1 FILM in 1 POUCH (0378-8765-16),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,63629-7270-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA204431,Bryant Ranch Prepack,63629-7270,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,30 TABLET in 1 BOTTLE (63629-7270-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,63629-7270-2,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA204431,Bryant Ranch Prepack,63629-7270,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/02/2022,N/A,ANDA,10 TABLET in 1 BOTTLE (63629-7270-2),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,43598-579-30,"2 mg/1,                         .5  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,ANDA205299,Dr.Reddys Laboratories Inc,43598-579,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/14/2018,N/A,ANDA,"30 POUCH in 1 CARTON (43598-579-30)  / 1 FILM, SOLUBLE in 1 POUCH (43598-579-01)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,70518-3603-0,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA201633,REMEDYREPACK INC.,70518-3603,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,01/04/2023,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-3603-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2024
Buprenorphine and Naloxone,42858-601-03,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205601,Rhodes Pharmaceuticals L.P.,42858-601,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,04/13/2020,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (42858-601-03)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,47781-355-03,"2 mg/1,                         .5  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA205954,Alvogen Inc.,47781-355,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/11/2019,N/A,ANDA,30 POUCH in 1 CARTON (47781-355-03)  / 1 FILM in 1 POUCH (47781-355-11),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,50383-294-93,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA204431,Akorn Operating Company LLC (dba Akorn),50383-294,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,01/07/2016,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (50383-294-93)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,62756-969-83,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA201633,"Sun Pharmaceutical Industries, Inc.",62756-969,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,07/18/2017,N/A,ANDA,30 TABLET in 1 BOTTLE (62756-969-83),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,63629-9482-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205601,Bryant Ranch Prepack,63629-9482,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/12/2022,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (63629-9482-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,70518-3487-0,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205601,REMEDYREPACK INC.,70518-3487,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,08/19/2022,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-3487-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,62756-969-64,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA201633,"Sun Pharmaceutical Industries, Inc.",62756-969,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,07/18/2017,N/A,ANDA,3 BLISTER PACK in 1 CARTON (62756-969-64)  / 10 TABLET in 1 BLISTER PACK,"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,62175-452-32,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205022,"Lannett Company, Inc.",62175-452,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,09/19/2016,N/A,ANDA,30 TABLET in 1 BOTTLE (62175-452-32),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1296-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1296,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,08/12/2019,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1296-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1296-2,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1296,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,06/29/2022,N/A,ANDA,10 TABLET in 1 BOTTLE (71335-1296-2),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,50268-144-15,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,AvPAK,50268-144,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/08/2016,N/A,ANDA,"50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-144-15)  / 1 TABLET in 1 BLISTER PACK (50268-144-11)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,70518-1007-0,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,REMEDYREPACK INC.,70518-1007,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/08/2018,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-1007-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,65162-416-09,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,Amneal Pharmaceuticals LLC,65162-416,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/22/2013,N/A,ANDA,90 TABLET in 1 BOTTLE (65162-416-09),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,63629-7269-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,Bryant Ranch Prepack,63629-7269,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/16/2019,N/A,ANDA,30 TABLET in 1 BOTTLE (63629-7269-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,65162-416-03,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,Amneal Pharmaceuticals LLC,65162-416,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/22/2013,N/A,ANDA,30 TABLET in 1 BOTTLE (65162-416-03),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,71335-1514-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,Bryant Ranch Prepack,71335-1514,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/17/2020,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1514-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,71335-1514-2,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203136,Bryant Ranch Prepack,71335-1514,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/21/2022,N/A,ANDA,10 TABLET in 1 BOTTLE (71335-1514-2),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,71335-1653-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203326,Bryant Ranch Prepack,71335-1653,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,10/29/2020,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1653-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,71335-1720-1,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203326,Bryant Ranch Prepack,71335-1720,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,10/19/2020,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1720-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,71335-1720-2,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203326,Bryant Ranch Prepack,71335-1720,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,07/01/2022,N/A,ANDA,10 TABLET in 1 BOTTLE (71335-1720-2),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,0054-0188-13,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203326,Hikma Pharmaceuticals USA Inc.,0054-0188,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,06/27/2014,N/A,ANDA,30 TABLET in 1 BOTTLE (0054-0188-13),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,0904-7009-06,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA203326,Major Pharmaceuticals,0904-7009,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,06/27/2014,N/A,ANDA,50 BLISTER PACK in 1 CARTON (0904-7009-06)  / 1 TABLET in 1 BLISTER PACK,"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,55700-901-30,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA207000,"Quality Care Products, LLC",55700-901,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,03/03/2021,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (55700-901-30)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,0406-8005-03,"2 mg/1,                         .5  mg/1",TABLET,SUBLINGUAL,ANDA207000,SpecGx LLC,0406-8005,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/13/2017,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (0406-8005-03)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Suboxone,12496-1202-3,"2 mg/1,                         .5  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,NDA022410,INDIVIOR INC.,12496-1202,"buprenorphine hydrochloride, naloxone hydrochloride",BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/13/2010,N/A,NDA,"30 POUCH in 1 CARTON (12496-1202-3)  / 1 FILM, SOLUBLE in 1 POUCH (12496-1202-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Zubsolv,54123-929-30,"2.9 mg/1,                         .71  mg/1","TABLET, ORALLY DISINTEGRATING",SUBLINGUAL,NDA204242,"Orexo US, Inc.",54123-929,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/04/2013,N/A,NDA,"3 BLISTER PACK in 1 CARTON (54123-929-30)  / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,42858-839-40,20 ug/h,PATCH,TRANSDERMAL,NDA021306,Rhodes Pharmaceuticals L.P.,42858-839,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,07/05/2017,N/A,NDA AUTHORIZED GENERIC,4 POUCH in 1 CARTON (42858-839-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0093-3659-40,20 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA204937,"Teva Pharmaceuticals USA, Inc.",0093-3659,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,11/26/2018,N/A,ANDA,4 POUCH in 1 CARTON (0093-3659-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,69238-1205-2,20 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA211586,Amneal Pharmaceuticals NY LLC,69238-1205,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,04/20/2020,N/A,ANDA,4 POUCH in 1 CARTON (69238-1205-2)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine transdermal system,47781-408-04,20 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA207490,Alvogen Inc.,47781-408,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,08/29/2022,N/A,ANDA,4 POUCH in 1 CARTON (47781-408-04)  / 1 PATCH in 1 POUCH (47781-408-11)  / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine transdermal system,58064-408-04,20 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA207490,"LTS Therapy Systems, LLC",58064-408,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,08/29/2022,N/A,ANDA,4 POUCH in 1 CARTON (58064-408-04)  / 1 PATCH in 1 POUCH (58064-408-11)  / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Butrans,59011-752-04,20 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,NDA021306,Purdue Pharma LP,59011-752,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/14/2011,N/A,NDA,4 POUCH in 1 CARTON (59011-752-04)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
SUBLOCADE,12496-0300-1,300 mg/1,SOLUTION,SUBCUTANEOUS,NDA209819,Indivior Inc.,12496-0300,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/26/2018,N/A,NDA,1 POUCH in 1 CARTON (12496-0300-1)  / 1 SYRINGE in 1 POUCH (12496-0300-2)  / 1 SOLUTION in 1 SYRINGE (12496-0300-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-023-60,300 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-023,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/01/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-023-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-023-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,43598-580-30,"4 mg/1,                         1  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,ANDA205806,Dr.Reddys Laboratories Inc,43598-580,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/14/2018,N/A,ANDA,"30 POUCH in 1 CARTON (43598-580-30)  / 1 FILM, SOLUBLE in 1 POUCH (43598-580-01)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,0378-8766-93,"4 mg/1,                         1  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA211785,Mylan Pharmaceuticals Inc.,0378-8766,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,04/17/2020,N/A,ANDA,30 POUCH in 1 CARTON (0378-8766-93)  / 1 FILM in 1 POUCH (0378-8766-16),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,47781-356-03,"4 mg/1,                         1  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA205954,Alvogen Inc.,47781-356,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/11/2019,N/A,ANDA,30 POUCH in 1 CARTON (47781-356-03)  / 1 FILM in 1 POUCH (47781-356-11),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Suboxone,12496-1204-3,"4 mg/1,                         1  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,NDA022410,INDIVIOR INC.,12496-1204,"buprenorphine hydrochloride, naloxone hydrochloride",BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,08/24/2012,N/A,NDA,"30 POUCH in 1 CARTON (12496-1204-3)  / 1 FILM, SOLUBLE in 1 POUCH (12496-1204-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-024-60,450 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-024,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,08/21/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-024-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-024-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,42858-750-40,5 ug/h,PATCH,TRANSDERMAL,NDA021306,Rhodes Pharmaceuticals L.P.,42858-750,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,07/05/2017,N/A,NDA AUTHORIZED GENERIC,4 POUCH in 1 CARTON (42858-750-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,69238-1202-2,5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA211586,Amneal Pharmaceuticals NY LLC,69238-1202,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,04/20/2020,N/A,ANDA,4 POUCH in 1 CARTON (69238-1202-2)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0093-3656-40,5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA204937,"Teva Pharmaceuticals USA, Inc.",0093-3656,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,11/26/2018,N/A,ANDA,4 POUCH in 1 CARTON (0093-3656-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine transdermal system,47781-406-04,5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA207490,Alvogen Inc.,47781-406,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,08/29/2022,N/A,ANDA,4 POUCH in 1 CARTON (47781-406-04)  / 1 PATCH in 1 POUCH (47781-406-11)  / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Butrans,59011-750-04,5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,NDA021306,Purdue Pharma LP,59011-750,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/14/2011,N/A,NDA,4 POUCH in 1 CARTON (59011-750-04)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Zubsolv,54123-957-30,"5.7 mg/1,                         1.4  mg/1","TABLET, ORALLY DISINTEGRATING",SUBLINGUAL,NDA204242,"Orexo US, Inc.",54123-957,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/04/2013,N/A,NDA,"3 BLISTER PACK in 1 CARTON (54123-957-30)  / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-025-60,600 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-025,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,08/24/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-025-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-025-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,42858-353-40,7.5 ug/h,PATCH,TRANSDERMAL,NDA021306,Rhodes Pharmaceuticals L.P.,42858-353,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,07/05/2017,N/A,NDA AUTHORIZED GENERIC,4 POUCH in 1 CARTON (42858-353-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0093-3239-40,7.5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA204937,"Teva Pharmaceuticals USA, Inc.",0093-3239,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,12/27/2021,N/A,ANDA,4 POUCH in 1 CARTON (0093-3239-40)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,69238-1505-2,7.5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,ANDA211586,Amneal Pharmaceuticals NY LLC,69238-1505,Buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,04/20/2020,N/A,ANDA,4 POUCH in 1 CARTON (69238-1505-2)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Butrans,59011-757-04,7.5 ug/h,"PATCH, EXTENDED RELEASE",TRANSDERMAL,NDA021306,Purdue Pharma LP,59011-757,buprenorphine,BUPRENORPHINE,HUMAN PRESCRIPTION DRUG,02/14/2011,N/A,NDA,4 POUCH in 1 CARTON (59011-757-04)  / 1 PATCH in 1 POUCH / 168 h in 1 PATCH,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-021-60,75 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-021,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/01/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-021-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-021-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-026-60,750 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-026,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/01/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-026-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-026-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,62756-460-83,8 mg/1,TABLET,SUBLINGUAL,ANDA201760,"Sun Pharmaceutical Industries, Inc.",62756-460,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/17/2016,N/A,ANDA,30 TABLET in 1 BOTTLE (62756-460-83),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,0228-3153-03,8 mg/1,TABLET,SUBLINGUAL,ANDA090819,"Actavis Pharma, Inc.",0228-3153,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/10/2015,N/A,ANDA,30 TABLET in 1 BOTTLE (0228-3153-03),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-0,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (71335-1154-0),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-1,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,03/15/2019,N/A,ANDA,90 TABLET in 1 BOTTLE (71335-1154-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-2,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,03/15/2019,N/A,ANDA,60 TABLET in 1 BOTTLE (71335-1154-2),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-3,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,07/22/2019,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1154-3),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-4,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,20 TABLET in 1 BOTTLE (71335-1154-4),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-5,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,01/16/2020,N/A,ANDA,7 TABLET in 1 BOTTLE (71335-1154-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-6,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,06/28/2021,N/A,ANDA,28 TABLET in 1 BOTTLE (71335-1154-6),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-7,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,1 TABLET in 1 BOTTLE (71335-1154-7),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-8,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,12 TABLET in 1 BOTTLE (71335-1154-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,71335-1154-9,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Bryant Ranch Prepack,71335-1154,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,14 TABLET in 1 BOTTLE (71335-1154-9),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,62756-460-64,8 mg/1,TABLET,SUBLINGUAL,ANDA201760,"Sun Pharmaceutical Industries, Inc.",62756-460,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/17/2016,N/A,ANDA,3 BLISTER PACK in 1 CARTON (62756-460-64)  / 10 TABLET in 1 BLISTER PACK,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,58118-0502-8,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,"Clinical Solutions Wholesale, LLC",58118-0502,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/07/2022,N/A,ANDA,30 TABLET in 1 BLISTER PACK (58118-0502-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine,60687-492-21,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,American Health Packaging,60687-492,Buprenorphine,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,02/06/2020,N/A,ANDA,"30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-492-21)  / 1 TABLET in 1 BLISTER PACK (60687-492-11)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE,42858-502-03,8 mg/1,TABLET,SUBLINGUAL,ANDA207276,Rhodes Pharmaceuticals L.P.,42858-502,BUPRENORPHINE,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/25/2017,N/A,ANDA,30 TABLET in 1 BOTTLE (42858-502-03),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,70518-2014-0,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,REMEDYREPACK INC.,70518-2014,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/12/2019,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-2014-0),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,70518-2014-1,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,REMEDYREPACK INC.,70518-2014,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/01/2021,N/A,ANDA,"60 TABLET in 1 BOTTLE, PLASTIC (70518-2014-1)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,68071-2915-3,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,"NuCare Pharmaceuticals,Inc.",68071-2915,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,01/17/2023,N/A,ANDA,30 TABLET in 1 BOTTLE (68071-2915-3),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2024
Buprenorphine HCl,0054-0177-13,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Hikma Pharmaceuticals USA Inc.,0054-0177,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/08/2009,N/A,ANDA,30 TABLET in 1 BOTTLE (0054-0177-13),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-0,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (71335-1163-0),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,0904-7155-04,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Major Pharmaceuticals,0904-7155,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/08/2009,N/A,ANDA,30 BLISTER PACK in 1 CARTON (0904-7155-04)  / 1 TABLET in 1 BLISTER PACK,"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,58118-0177-8,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,"Clinical Solutions Wholesale, LLC",58118-0177,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,10/15/2018,N/A,ANDA,30 TABLET in 1 BLISTER PACK (58118-0177-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-1,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,03/21/2019,N/A,ANDA,90 TABLET in 1 BOTTLE (71335-1163-1),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-2,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/24/2019,N/A,ANDA,60 TABLET in 1 BOTTLE (71335-1163-2),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-3,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,04/01/2019,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1163-3),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-4,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,20 TABLET in 1 BOTTLE (71335-1163-4),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-5,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,7 TABLET in 1 BOTTLE (71335-1163-5),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-6,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,28 TABLET in 1 BOTTLE (71335-1163-6),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-7,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,1 TABLET in 1 BOTTLE (71335-1163-7),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-8,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,12 TABLET in 1 BOTTLE (71335-1163-8),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl,71335-1163-9,8 mg/1,TABLET,SUBLINGUAL,ANDA078633,Bryant Ranch Prepack,71335-1163,Buprenorphine HCl,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/16/2022,N/A,ANDA,14 TABLET in 1 BOTTLE (71335-1163-9),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride,50383-930-93,8 mg/1,TABLET,SUBLINGUAL,ANDA090622,Akorn Operating Company LLC (dba Akorn),50383-930,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/24/2010,N/A,ANDA,30 TABLET in 1 BOTTLE (50383-930-93),"Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,0228-3155-03,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA091422,"Actavis Pharma, Inc.",0228-3155,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,03/04/2013,N/A,ANDA,30 TABLET in 1 BOTTLE (0228-3155-03),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,70518-3389-0,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205601,REMEDYREPACK INC.,70518-3389,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,03/16/2022,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-3389-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2024
Buprenorphine and Naloxone,42858-602-03,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205601,Rhodes Pharmaceuticals L.P.,42858-602,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,04/13/2020,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (42858-602-03)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,62756-970-64,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA201633,"Sun Pharmaceutical Industries, Inc.",62756-970,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,07/18/2017,N/A,ANDA,3 BLISTER PACK in 1 CARTON (62756-970-64)  / 10 TABLET in 1 BLISTER PACK,"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,47781-357-03,"8 mg/1,                         2  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA205954,Alvogen Inc.,47781-357,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/11/2019,N/A,ANDA,30 POUCH in 1 CARTON (47781-357-03)  / 1 FILM in 1 POUCH (47781-357-11),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-0,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,42 TABLET in 1 BOTTLE (71335-1378-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-1,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,10/25/2019,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1378-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-2,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,60 TABLET in 1 BOTTLE (71335-1378-2),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-3,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,90 TABLET in 1 BOTTLE (71335-1378-3),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-4,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (71335-1378-4),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-5,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,14 TABLET in 1 BOTTLE (71335-1378-5),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-6,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,28 TABLET in 1 BOTTLE (71335-1378-6),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-7,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,6 TABLET in 1 BOTTLE (71335-1378-7),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-8,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,10 TABLET in 1 BOTTLE (71335-1378-8),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,71335-1378-9,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,Bryant Ranch Prepack,71335-1378,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/30/2022,N/A,ANDA,21 TABLET in 1 BOTTLE (71335-1378-9),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,70518-2311-0,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,REMEDYREPACK INC.,70518-2311,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,09/12/2019,N/A,ANDA,30 TABLET in 1 BLISTER PACK (70518-2311-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,60429-587-30,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA204431,"Golden State Medical Supply, Inc.",60429-587,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,01/07/2016,09/30/2023,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (60429-587-30)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,N/A
Buprenorphine and Naloxone,0378-8767-93,"8 mg/1,                         2  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA207607,Mylan Pharmaceuticals Inc.,0378-8767,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/20/2019,N/A,ANDA,30 POUCH in 1 CARTON (0378-8767-93)  / 1 FILM in 1 POUCH (0378-8767-16),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,50383-287-93,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA204431,Akorn Operating Company LLC (dba Akorn),50383-287,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,01/07/2016,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (50383-287-93)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,60505-7053-5,"8 mg/1,                         2  mg/1",FILM,BUCCAL; SUBLINGUAL,ANDA212756,Apotex Corp.,60505-7053,buprenorphine and naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,12/12/2022,N/A,ANDA,30 POUCH in 1 CARTON (60505-7053-5)  / 1 FILM in 1 POUCH (60505-7053-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,63629-9483-1,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205601,Bryant Ranch Prepack,63629-9483,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/12/2022,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (63629-9483-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,62175-458-32,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205022,"Lannett Company, Inc.",62175-458,Buprenorphine and Naloxone,BUPRENORPHINE;  NALOXONE,HUMAN PRESCRIPTION DRUG,09/19/2016,N/A,ANDA,30 TABLET in 1 BOTTLE (62175-458-32),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,60687-637-65,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA205601,American Health Packaging,60687-637,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,11/01/2021,N/A,ANDA,50 BLISTER PACK in 1 CARTON (60687-637-65)  / 1 TABLET in 1 BLISTER PACK (60687-637-11),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,43598-582-30,"8 mg/1,                         2  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,ANDA205299,Dr.Reddys Laboratories Inc,43598-582,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE,HUMAN PRESCRIPTION DRUG,06/14/2018,N/A,ANDA,"30 POUCH in 1 CARTON (43598-582-30)  / 1 FILM, SOLUBLE in 1 POUCH (43598-582-01)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine and Naloxone,62756-970-83,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA201633,"Sun Pharmaceutical Industries, Inc.",62756-970,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,07/18/2017,N/A,ANDA,30 TABLET in 1 BOTTLE (62756-970-83),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,65162-415-03,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA203136,Amneal Pharmaceuticals LLC,65162-415,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/22/2013,N/A,ANDA,30 TABLET in 1 BOTTLE (65162-415-03),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,50268-145-15,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA203136,AvPAK,50268-145,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/08/2016,N/A,ANDA,"50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-145-15)  / 1 TABLET in 1 BLISTER PACK (50268-145-11)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine HCl and Naloxone HCl,65162-415-09,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA203136,Amneal Pharmaceuticals LLC,65162-415,Buprenorphine and Naloxone,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/22/2013,N/A,ANDA,90 TABLET in 1 BOTTLE (65162-415-09),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-9,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"21 TABLET in 1 BOTTLE, PLASTIC (71335-1858-9)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-1,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,10/23/2020,N/A,ANDA,30 TABLET in 1 BOTTLE (71335-1725-1),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,0054-0189-13,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA203326,Hikma Pharmaceuticals USA Inc.,0054-0189,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,06/27/2014,N/A,ANDA,30 TABLET in 1 BOTTLE (0054-0189-13),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,0406-8020-03,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,SpecGx LLC,0406-8020,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,12/13/2017,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (0406-8020-03)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-0,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,42 TABLET in 1 BOTTLE (71335-1725-0),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-2,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,05/25/2022,N/A,ANDA,60 TABLET in 1 BOTTLE (71335-1725-2),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-3,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,90 TABLET in 1 BOTTLE (71335-1725-3),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-4,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,120 TABLET in 1 BOTTLE (71335-1725-4),"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-5,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,"14 TABLET in 1 BOTTLE, PLASTIC (71335-1725-5)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-6,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,"28 TABLET in 1 BOTTLE, PLASTIC (71335-1725-6)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-7,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,"6 TABLET in 1 BOTTLE, PLASTIC (71335-1725-7)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-0,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"42 TABLET in 1 BOTTLE, PLASTIC (71335-1858-0)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-1,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,05/07/2021,N/A,ANDA,"30 TABLET in 1 BOTTLE, PLASTIC (71335-1858-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
buprenorphine hydrochloride and naloxone hydrochloride dihydrate,0904-7010-06,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA203326,Major Pharmaceuticals,0904-7010,buprenorphine hydrochloride and naloxone hydrochloride dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,06/27/2014,N/A,ANDA,50 BLISTER PACK in 1 CARTON (0904-7010-06)  / 1 TABLET in 1 BLISTER PACK,"Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-8,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,"10 TABLET in 1 BOTTLE, PLASTIC (71335-1725-8)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,71335-1725-9,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA207000,Bryant Ranch Prepack,71335-1725,Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,09/28/2022,N/A,ANDA,"21 TABLET in 1 BOTTLE, PLASTIC (71335-1725-9)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-2,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,06/08/2021,N/A,ANDA,"60 TABLET in 1 BOTTLE, PLASTIC (71335-1858-2)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-3,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"90 TABLET in 1 BOTTLE, PLASTIC (71335-1858-3)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-4,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"120 TABLET in 1 BOTTLE, PLASTIC (71335-1858-4)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-5,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"14 TABLET in 1 BOTTLE, PLASTIC (71335-1858-5)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-6,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"28 TABLET in 1 BOTTLE, PLASTIC (71335-1858-6)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-7,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"6 TABLET in 1 BOTTLE, PLASTIC (71335-1858-7)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,71335-1858-8,"8 mg/1,                         2  mg/1",TABLET,SUBLINGUAL,ANDA209069,Bryant Ranch Prepack,71335-1858,BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE DIHYDRATE,HUMAN PRESCRIPTION DRUG,02/14/2022,N/A,ANDA,"10 TABLET in 1 BOTTLE, PLASTIC (71335-1858-8)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Suboxone,12496-1208-3,"8 mg/1,                         2  mg/1","FILM, SOLUBLE",BUCCAL; SUBLINGUAL,NDA022410,INDIVIOR INC.,12496-1208,"buprenorphine hydrochloride, naloxone hydrochloride",BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,09/13/2010,N/A,NDA,"30 POUCH in 1 CARTON (12496-1208-3)  / 1 FILM, SOLUBLE in 1 POUCH (12496-1208-1)","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
Zubsolv,54123-986-30,"8.6 mg/1,                         2.1  mg/1","TABLET, ORALLY DISINTEGRATING",SUBLINGUAL,NDA204242,"Orexo US, Inc.",54123-986,buprenorphine hydrochloride and naloxone hydrochloride,BUPRENORPHINE HYDROCHLORIDE;  NALOXONE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,12/11/2014,N/A,NDA,"3 BLISTER PACK in 1 CARTON (54123-986-30)  / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK","Opioid Antagonist [EPC],  Opioid Antagonists [MoA],  Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023
BELBUCA,59385-027-60,900 ug/1,"FILM, SOLUBLE",BUCCAL,NDA207932,BioDelivery Sciences International Inc,59385-027,buprenorphine hydrochloride,BUPRENORPHINE HYDROCHLORIDE,HUMAN PRESCRIPTION DRUG,08/11/2017,N/A,NDA,"60 POUCH in 1 CARTON (59385-027-60)  / 1 FILM, SOLUBLE in 1 POUCH (59385-027-01)","Partial Opioid Agonist [EPC],  Partial Opioid Agonists [MoA]",CIII,No,12/31/2023